Periampullary pancreatic somatostatinoma

Annals of Surgical Oncology

Volumn 9, Issue 9, 2002, Pages 869-874

  House, Michael G ^a   Yeo, Charles J ^a   Schulick, Richard D ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

Author keywords

Islet cell; Neuroendocrine; Pancreas; Pancreaticoduodenectomy; Somatostatinoma; Whipple procedure

Indexed keywords

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER SURGERY; CASE REPORT; CELL DIFFERENTIATION; CLINICAL FEATURE; DISEASE ASSOCIATION; DISEASE COURSE; FEMALE; HUMAN; MALE; METASTASIS; PANCREAS ISLET CELL TUMOR; PANCREATICODUODENECTOMY; PROGNOSIS; SOMATOSTATINOMA; TREATMENT OUTCOME; TUMOR VOLUME; VATER PAPILLA;

EID: 0036840792     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02557523     Document Type: Article

References (31)

1. Pearse AG. The APUD concept and its implications in pathology. Pathol Annu 1974;9:27-41.
2. Konomi K, Chijiiwa K, Katsuta T, Yamaguchi K. Pancreatic somatostatinoma: A case report and review of the literature. J Surg Oncol 1990;43:259-65.
3. Wynick D, Williams SJ, Bloom SR. Symptomatic secondary hormone syndromes in patients with established malignant pancreatic endocrine tumors. N Engl J Med 1988;319:605-7.
4. Anene C, Thompson JS, Saigh J, Badakhsh S, Ecklund RE. Somatostatinoma: Atypical presentation of a rare pancreatic tumor. Am J Gastroenterol 1995;90:819-21.
5. Harris GJ, Tio F, Cruz AB. Somatostatinoma: A case report and review of the literature. J Surg Oncol 1987;36:8-16.
6. Larsson LI, Holst JJ, Kuhl C, et al. Pancreatic somatostatinoma: Clinical features and physiological implications. Lancet 1977;1: 666-8.
7. Ganda OP, Weir GC, Soeldner JS, et al. Somatostatinoma. A somatostatin-containing tumor of the endocrine pancreas. N Engl J Med 1979;296:963-7.
8. Krejs GJ, Orcil L, Conlon JM. Somatostatinoma syndrome: Biochemical, morphologic, and chemical features. N Engl J Med 1979;301:285-92.
9. Delcore R, Friesen SR. Gastrointestinal neuroendocrine tumors. J Am Coll Surg 1994;178:187-211.
10. Malone MJ, Silverman ML, Braasch JW, Jin G, Dayal Y. Early somatostatinoma of the duct of Santorini. Arch Surg 1985;120: 1381-3.
11. Vinik AI, Moattari AR. Treatment of endocrine tumors of the pancreas. Endocrinol Metab Clin North Am 1989;18:483-518.
12. Griffiths DFR, Williams GT, Williams ED. Duodenal carcinoid tumours, phaeochromocytoma and neurofibromatosis: Islet cell tumour, phaeochromocytoma and the von Hippel-Lindau complex - Two distinctive neuroendocrine syndromes. Q J Med 1987; 64:769-82.
13. Soga J, Yakuwa Y. Somatostatinoma inhibitory syndrome: A statistical evaluation of 173 reported cases as compared to other pancreatic endocrinomas. J Exp Clin Cancer Res 1999;18:13-22.
14. Lucey R, Yamada T. Biochemistry and physiology of gastrointestinal somatostatin. Dig Dis Sci 1989;34:55-135.
15. Dayal Y, Ganda OP. Somatostatin-Producing Tumors. Endocrine Pathology of the Gut and Pancreas. Boca Raton, FL: CRC Press, 1991:241-77.
16. Reubi JC. Neuropeptide receptors in health and disease: The molecular basis for in vivo imaging. J Nucl Med 1995;36:1825-35.
17. Angeletti S, Corleto VD, Schillaci O, et al. Use of the somatostatin analogue octreotide to localise and manage somatostatin-producing tumours. Gut 1998;42:792-4.
18. Estes BL, Krejs GJ. The inhibitory syndrome: Somatostatinoma. In: Friesen SR, Thompson NW. eds. Surgical Endocrinology: Clinical Syndromes. Philadelphia: Lippincott, 1990:249-66.
19. Guo M, Lemos LB, Bigler S, Baliga M. Duodenal somatostatinoma of the ampulla of Vater diagnosed by endoscopic fine needle aspiration: A case report. Acta Cytol 2001;45:622-6.
20. Kent RB, van Heerden JA, Weiland LH. Non-functioning islet cell tumors. Ann Surg 1980;22:185-89.
21. Madeira I, Terris B, Voss M, et al. Prognostic factors with endocrine tumours of the duodenopancreatic area. Gut 1998;43:422-7.
22. Chamberlain RS, Canes D, Brown KT. Hepatic metastasis: Does intervention alter outcome? J Am Coll Surg 2000;190:432-5.
23. Doussett B, Saint-Marre O, Pitre J. Metastatic endocrine tumors: Medical treatment, surgical resections, or liver transplantation. World J Surg 1996;20:908-15.
24. Norton JA, Sugarbaker PH, Doppman JL. Aggressive resection of metastatic disease in selected patients with malignant gastrinoma. Ann Surg 1986;203:353-9.
25. Eriksson B, Oberg K, Skogseid B. Neuroendocrine pancreatic tumors, clinical findings in a prospective study of 84 patients. Acta Oncol 1989;3:373-7.
26. Weber HC, Venzon DJ, Lin JT. Determinants of metastatic rate and survival in patients with Zollinger-Ellison syndrome: A prospective long-term study. Gastroenterology 1995;108:1637-49.
27. Tanaka S, Yamashaki S, Matsushita H. Duodenal somatostatinoma: A case report and review of 31 cases with special reference to the relationship between tumor size and metastasis. Pathol Int 2000;50:146-52.
28. Moertel CG, Lefkopoulo M, Lipsitz S. Streptozocin-doxorubicin, streptozocin-fluorouracil or chlorozotocin in the treatment of advanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
29. Bukowski RM, Tangen CM, Peterson RF. Phase II trial of DTIC in patients with metastatic carcinoid: A Southwest Oncology Group study. Cancer 1994;73:1505-8.
30. Eriksson B, Oberg K. An update of the medical treatment of malignant endocrine pancreatic tumors. Acta Oncol 1993;32:203-8.
31. Brentjens R, Saltz L. Islet cell tumors of the pancreas: The medical oncologist's perspective. Surg Clin North Am 2001;81:527-42.